Vicks holds. Genexa scales. AXIV reads like Equate.

Territory A. Argentine pharma heritage, bilingual natural-immune. AXIV becomes the Argentine-pharma cold/flu brand. Clinical precision from Córdoba. No synthetic gimmicks. Written for the bilingual household. Vivunt and Savant Pharm carry a true 30-year manufacturing heritage and 12 years of biannual GRI/UN-SDG sustainability reporting. None of the U.S. natural-immune incumbents have this asset. Boiron has French heritage and a single Spanish page. No other brand in the set is bilingual or Latin-American-rooted. The asset is structural and unanswerable.

Territory B. Adult clean medicine. Same actives as Vicks, Tylenol, Mucinex. Made without the artificial dyes and inactives. Written for the working adult. Reachable. Genexa already owns Clean Medicine and would close the lane in 12-18 months if AXIV enters second. Possible if differentiated to "adult professional clean" against Genexa's family-pediatric skew. AXIV enters Genexa's lane four years late.

Territory C. Work-recovery for working adults. Strong enough to get through the day. Calm enough to get through the night. Honest about what works. Voice-led, not asset-led. Any incumbent with bigger marketing budget can take the frame. The territory does not use AXIV's Argentine pharma heritage as a defensible asset. It competes on brand voice in a category where voice is cheap.

The recommendation is Territory A. Three reasons. First, the territory rests on a structural asset that AXIV uniquely owns. Territory B is reachable but Genexa would close it. Territory C is positioning-only and any incumbent can take it. Territory A's defense is the asset, not the language.

Second, the territory is Hispanic-led without being Hispanic-only. The bilingual frame opens the brand to a household that currently has no branded natural-immune answer while keeping the English-speaking shopper inside the heritage credibility story. The growth segment is the U.S. Hispanic natural-products buyer and the brand also reads as legitimate to the non-Hispanic shopper looking for a clean alternative.

Third, the territory aligns with AXIV's existing SKU breadth. Day Flu, Night Flu, Allergy, Sinus, Sleep, DM Cough maps to a symptom-specific natural cold/flu ladder without product development. Territory A reads in the SKU lineup AXIV already ships. Cite Genexa's 4-year arc to 60,000 stores as the canonical challenger precedent. Source: deliverables/06-rebrand-recs.md.

The supporting claim stack runs five lines. Manufactured by Savant Pharm in Córdoba, Argentina. Thirty years of pharmaceutical production. Same active ingredients as the brands you know. Cleaner inactive ingredients you can read. A Drug Facts panel that says what it does. A Spanish-language version that says it the same way. Symptom-specific. No kitchen-sink combos. No copy-paste actives. Twelve consecutive biannual sustainability reports since 2013. Available on request.

The claims AXIV stops saying are five lines. The compare-to drops. The unsourced 141,000+ Happy Customers drops. The Compare to Benadryl and Compare to Vicks Sinex drop. The Cicero Latin in the "Why Choose AXIV" block drops. The DSHEA dietary-supplement disclaimer drops from OTC drug pages and stays only on the melatonin SKU where it is regulatorily appropriate.

The naming architecture consolidates. AXIV stays as master wordmark. VroZzzz / VroZzz / VrozzZ collapses to AXIV Sleep with two SKUs: AXIV Sleep (diphenhydramine softgel) and AXIV Sleep Natural (melatonin gummy). The brand-confusion cost is higher than any equity in the VroZzz name. GemSleep gets killed (no live product page; the hero banner is stale). DM Max folds into AXIV Cough. C-Pack becomes "AXIV [Symptom] On-the-Go." The system reads master + symptom + form. The system reads top-down on pack and on shelf.

The packaging direction is a white or warm-off-white master base. Color-coded by symptom following category convention so consumer recognition is preserved. Master wordmark in a sans-serif block at consistent top-left position across the system. Manufacturing-origin signature line on front-of-pack. Bilingual Drug Facts panel. Distinct from the private-label register through the heritage line and the bilingual treatment. The visual differentiation is what makes the rhetorical differentiation believable.

The realistic mix today is one channel. AXIV is operationally live on Amazon (19 ASINs, roughly 12,500 visible ratings on the four lead SKUs) and operationally absent from cvs.com, walgreens.com, walmart.com, target.com. Brick-and-mortar is closed until the rebrand lands. Two channels are reachable inside 12 months without a finished rebrand: Amazon optimization (Brand Registry, Brand Store, A+ Content, Sponsored Brands) and Target Plus Marketplace as a 3P beachhead. Both depend on resolving the execution drift first.

CVS, Walgreens, and Walmart 1P are 18-36 month moves. Not quarterly moves. The Genexa precedent (4 years from 2020 multi-chain entry to 60,000 stores in 2026) is the realistic arc for a challenger entering the same shelf with the same active ingredients. The path runs Amazon optimization at M0 to M6, Target Plus Marketplace and Hispanic-market independent pharmacy at M6 to M12, Walgreens via WBA Global Sourcing at M12 to M24, Target 1P transition from Plus at M18 to M30, CVS Health at M24 to M36, Walmart at M24 to M36 either branded-shelf or private-brand via Walmart International Sourcing.

Three gates block every brick-and-mortar channel until they close. Each gate has a known fix. Each fix has a known owner. Each gate sits upstream of every channel decision in deliverables/07-gtm-priorities.md.

AXIV's composite of 27.95 sits 31.05 points below the next-lowest brand in the 18-brand vertical. The gap is concentrated in two dimensions. Brand System Coherence at 12 is a category outlier with no peer, and it is fixable in one production sprint. Differentiation at 25 is structural, and it requires the rebrand work to move.

The first move costs no rebrand commit. Fix the lorem ipsum. Fix the copy-paste actives. Fix the footer placeholders. Fix the wordmark drift. Retire the legacy AXIM slugs. Move System Coherence from 12 to roughly 50. Move composite from 27.95 to roughly 31.75. AXIV reaches T4 in one sprint. The execution-hygiene work also clears the credibility floor under any rebrand decision that follows. Without it, no buyer takes the brand seriously enough to schedule the meeting.

The second move is the rebrand. Territory A is the recommended path. Latin-American clean medicine for the U.S. Hispanic-and-bilingual household. The territory rests on a structural asset (Vivunt and Savant Pharm's 30-year Córdoba manufacturing) that no U.S. competitor can answer. The territory aligns with AXIV's existing SKU breadth. The territory turns AXIV's two structural disadvantages (Argentine ownership and a compare-to register) into the brand's reason for being.

The third move is trade-press cadence. The single biggest gap relative to every successful precedent. Zero AXIV footprint today. Three releases pegged to the rebrand. Twelve months of cadence before any CVS or Walgreens buyer outreach. The cadence does not change the score directly. The cadence makes the rebrand discoverable to the buyers who would otherwise read the brand as a Shopify drop.

The Genexa arc is the realistic timeline. Four years from 2020 multi-chain entry to 60,000 stores in 2026. AXIV is not 12 months from CVS. AXIV is one sprint from T4, twelve months from T3, and on the realistic Genexa-precedent path 24 to 36 months from T2 and brick-and-mortar 1P. The work is sequential and the milestones are knowable.

The hidden asset is the most interesting thing on the AXIV surface. Two quantified onset claims at SKU level. Thirty minutes for Sinus Severe. Twenty minutes for VroZzz. Neither incumbent in mainstream OTC publishes minute-level numeric claims at the homepage. Neither natural-immune brand does either. The two claims sit one product page deep, surfaced nowhere on the homepage, anchoring nothing at the master-brand level. The rebrand work is not invention. The rebrand work is surfacing what AXIV already owns.

Review chain. SHUR and Claude to Nuri (doc review), to Limore (external-share gate), to AXIV leadership. This editorial brief is the surface AXIV leadership will read first. The eight deliverables at projects/axiv/deliverables/ are the load-bearing reasoning beneath it. If any conclusion is contested, the place to argue is in the source deliverable, not here.

Confidence notes. Outside-in only. No Amazon Seller Central data, no axiv.live analytics, no Virixene operational data. Physical-sample inspection required for NDC, tamper-evident, and child-resistant verification (could shift Distribution ±2-3 points). Active-ingredient ground truth between vivunt.live and axiv.live unresolved (could shift Claims ±3-5 points). Amazon Brand Store, A+ Content, and Subscribe & Save eligibility for AXIV ASINs are JS-rendered and not confirmable outside-in.